Long-term remission after intensive chemotherapy in advanced myelodysplastic syndromes is generally associated with restoration of polyclonal haemopoiesis

Br J Haematol. 2000 Sep;110(4):884-6. doi: 10.1046/j.1365-2141.2000.02302.x.

Abstract

The clonality of peripheral blood cells was assessed in eight female patients with myelodysplastic syndrome (MDS) by means of the human androgen receptor gene-based assay (HUMARA). The patients were in complete remission for a median follow-up time of 83 months after intensive chemotherapy. X-chromosome inactivation patterns (XCIPs) indicated polyclonal haemopoiesis in five patients. Two patients had skewed lyonization (i.e. unbalanced XCIPs in both granulocytes and T cells) and one patient presented monoclonal granulocytes together with polyclonal T cells. We conclude that long-term remission in MDS following intensive chemotherapy is usually associated with polyclonal haemopoiesis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cyclophosphamide / administration & dosage
  • Cytarabine / administration & dosage
  • Daunorubicin / administration & dosage
  • Dosage Compensation, Genetic
  • Female
  • Follow-Up Studies
  • Hematopoiesis*
  • Humans
  • Idarubicin / administration & dosage
  • Middle Aged
  • Mitoxantrone / administration & dosage
  • Myelodysplastic Syndromes / blood*
  • Myelodysplastic Syndromes / drug therapy*
  • Myelodysplastic Syndromes / genetics
  • Retrospective Studies
  • Thioguanine / administration & dosage
  • Time Factors

Substances

  • Cytarabine
  • Cyclophosphamide
  • Mitoxantrone
  • Thioguanine
  • Idarubicin
  • Daunorubicin